|Bid||1.7500 x 2200|
|Ask||2.0000 x 1800|
|Day's Range||1.7500 - 1.8300|
|52 Week Range||0.8620 - 7.0700|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 24, 2020 / Midatech Pharma PLC (AIM:MTPH.
The primary endpoint of the study was to determine the dosage regimen to be used in a proposed Phase II study of the safety and efficacy of MTX110 in patients with DIPG.
R&D; Collaboration Strategy Gaining TractionABINGDON, OXFORDSHIRE / ACCESSWIRE / September 10, 2020 / Midatech Pharma PLC (AIM:MTPH.